Vivoryon Therapeutics N.V. (AMS:VVY)

Vivoryon Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	-3.62	-	10.76
Cost of Revenue	-	-	-0.53	-	1.57
Gross Profit	-	-	-3.1	-	9.2
Selling, General & Admin	4.8	6.9	8.6	8.91	4.55
Research & Development	4.38	14.06	17.64	20.22	17.45
Other Operating Expenses	-0.27	-	-0.5	-0.02	-0.01
Operating Expenses	8.91	20.96	25.74	29.11	21.99
Operating Income	-8.91	-20.96	-28.84	-29.11	-12.8
Interest Expense	-0.05	-0.05	-0.06	-0.02	-0.02
Interest & Investment Income	0.1	0.43	0.48	0.04	0.02
Currency Exchange Gain (Loss)	0	0.02	-0.2	0.69	0.75
Other Non Operating Income (Expenses)	-	-	-	0.05	-0.1
EBT Excluding Unusual Items	-8.85	-20.57	-28.62	-28.35	-12.15
Gain (Loss) on Sale of Investments	-	-	0.04	-0.01	-0.08
Gain (Loss) on Sale of Assets	-	-0	-	-	-
Pretax Income	-8.85	-20.57	-28.58	-28.36	-12.22
Income Tax Expense	-	-	-0.23	-0.2	0.43
Net Income	-8.85	-20.57	-28.34	-28.16	-12.66
Net Income to Common	-8.85	-20.57	-28.34	-28.16	-12.66
Shares Outstanding (Basic)	27	26	25	22	20
Shares Outstanding (Diluted)	27	26	25	22	20
Shares Change (YoY)	3.53%	3.27%	14.64%	10.10%	0.12%
EPS (Basic)	-0.33	-0.79	-1.12	-1.28	-0.63
EPS (Diluted)	-0.33	-0.79	-1.12	-1.28	-0.63
Free Cash Flow	-8.46	-19.18	-21.56	-21.81	-11.28
Free Cash Flow Per Share	-0.31	-0.74	-0.85	-0.99	-0.56
Gross Margin	-	-	-	-	85.42%
Operating Margin	-	-	-	-	-118.91%
Profit Margin	-	-	-	-	-117.57%
Free Cash Flow Margin	-	-	-	-	-104.77%
EBITDA	-8.83	-20.87	-28.76	-29.04	-12.73
EBITDA Margin	-	-	-	-	-118.22%
D&A For EBITDA	0.09	0.09	0.08	0.07	0.07
EBIT	-8.91	-20.96	-28.84	-29.11	-12.8
EBIT Margin	-	-	-	-	-118.91%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.